Indaptus Therapeutics provides update on INDP-D101 clinical trial

Indaptus Therapeutics (INDP) announced recent updates for the ongoing INDP-D101 clinical trial. “We currently have completed the monotherapy portion of our trial and have initiated seven patients in our initial cohort of combination therapy with tislelizumab, BeOne’s anti PD-1 monoclonal antibody. We are encouraged to report a patient in our monotherapy study who previously received an anti-PD-1 therapy had a clear reduction in size of liver metastases, consistent with a Partial Response. Unfortunately, there was evidence of disease progression at the next scheduled imaging, and the patient discontinued the study,” said Roger Waltzman, CMO. “However, the investigator believes the therapy provided clinical benefit for the patient over that 4-month period. Additionally, we have dosed 7 patients in the combination therapy initial safety cohort. Of the first three evaluable patients, one patient had stable disease at the first assessment, and the other two patients had disease progression. We continue to dose additional patients and will report their results in the coming weeks.”